A compound of formula or a salt thereof, or any of its stereoisomeric forms or a mixture thereof wherein: R 1 and R 1 ' are independently selected from the group consisting of H, (C 1 -C 4)alkyl, CF 3, F, Cl, Br, I, -CN, OH, NH 2, -OCH 3, and NO 2; with the proviso that at least one of R 1 and R 1 ' are different of H; A is a radical selected from linear or branched (C 1 -C 6)alkyl or one of the known carbocyclic or heterocyclic ring systems with 1-2 rings, wherein each of the rings forming the ring system has 5-7 members, each member independently selected from C, N, O, S, CH, CH 2, NH; is saturated, partially unsaturated or aromatic; being A substituted by one or more radical selected from the group consisting of H, halogen, nitro, cyano, linear or branched (C 1 -C 6)alkyl, halo-(C 1 -C 6)alkyl, linear or branched (C 2 -C 6)alkenyl, -OR 2, -COR 2, -COOR 2, -OC R 2, -C NR 3 R 4, -NR 3 R 4, -R 5 NHR 6, -SR 2, -SO-R 2, -SO 2 -R 2, and -SO 2 NR 3 R 4; wherein each R 2 independently represents H or linear or branched (C 1 -C 4)alkyl, each R 3 independently represents H or linear or branched (C 1 -C 4)alkyl, each R 4 independently represents H, linear or branched (C 1 -C 6)alkyl, phenyl, pyridine or quinoline; wherein the phenyl, pyridine and quinoline ring system is substituted by one or more radical selected from H, linear or branched (C 1 -C 4)alkyl, and NH 2; R 5 and R 6 are independently selected from H, linear or branched (C 1 -C 4)alkyl, for use in the treatment of a condition mediated by Rho-GTPase cell proteins, wherein the Rho-GTPase cell protein is Rac1 and the condition is a proliferative disorder selected from the group consisting of precancerosis; dysplasia; metaplasia; carcinomas of the gastrointestinal or colorectal tract, liver, pancreas, kidney, bladder, prostate, endometrium, ovary, testes, melanoma, dysplastic oral mucosa, invasive oral cancers, small cell and non-small cell lung carcinomas, hormone-dependent breast cancers, hormone-independent breast cancers, transitional and squamous cell cancers, neurological malignancies including neuroblastoma, gliomas, glioblastoma, astrocytomas, osteosarcomas, soft tissue sarcomas, hemangioamas, endocrinological tumors, hematologic neoplasias including leukemias, lymphomas, and other myeloproliferative and lymphoproliferative diseases, carcinomas in situ, hyperplastic lesions, adenomas, fibromas, histiocytosis, chronic inflammatory proliferative diseases, vascular proliferative diseases and virus-induced proliferative diseases, skin diseases characterized by hyperproliferation of keratinocytes and/or T cells. R 1 and R 1 ' are independently selected from the group consisting of H, (C 1 -C 4)alkyl, CF 3, F, Cl, Br, I, -CN, OH, NH 2, -OCH 3, and NO 2; with the proviso that at least one of R 1 and R 1 ' are different of H; A is a radical selected from linear or branched (C 1 -C 6)alkyl or one of the known carbocyclic or heterocyclic ring systems with 1-2 rings, wherein each of the rings forming the ring system has 5-7 members, each member independently selected from C, N, O, S, CH, CH 2, NH; is saturated, partially unsaturated or aromatic; being A substituted by one or more radical selected from the group consisting of H, halogen, nitro, cyano, linear or branched (C 1 -C 6)alkyl, halo-(C 1 -C 6)alkyl, linear or branched (C 2 -C 6)alkenyl, -OR 2, -COR 2, -COOR 2, -OC R 2, -C NR 3 R 4, -NR 3 R 4, -R 5 NHR 6, -SR 2, -SO-R 2, -SO 2 -R 2, and -SO 2 NR 3 R 4; wherein each R 2 independently represents H or linear or branched (C 1 -C 4)alkyl, each R 3 independently represents H or linear or branched (C 1 -C 4)alkyl, each R 4 independently represents H, linear or branched (C 1 -C 6)alkyl, phenyl, pyridine or quinoline; wherein the phenyl, pyridine and quinoline ring system is substituted by one or more radical selected from H, linear or branched (C 1 -C 4)alkyl, and NH 2; R 5 and R 6 are independently selected from H, linear or branched (C 1 -C 4)alkyl, for use in the treatment of a condition mediated by Rho-GTPase cell proteins, wherein the Rho-GTPase cell protein is Rac1 and the condition is a proliferative disorder selected from the group consisting of precancerosis; dysplasia; metaplasia; carcinomas of the gastrointestinal or colorectal tract, liver, pancreas, kidney, bladder, prostate, endometrium, ovary, testes, melanoma, dysplastic oral mucosa, invasive oral cancers, small cell and non-small cell lung carcinomas, hormone-dependent breast cancers, hormone-independent breast cancers, transitional and squamous cell cancers, neurological malignancies including neuroblastoma, gliomas, glioblastoma, astrocytomas, osteosarcomas, soft tissue sarcomas, hemangioamas, endocrinological tumors, hematologic neoplasias including leukemias, lymphomas, and other myeloproliferative and lymphoproliferative diseases, carcinomas in situ, hyperplastic lesions, adenomas, fibromas, histiocytosis, chronic inflammatory proliferative diseases, vascular proliferative diseases and virus-induced proliferative diseases, skin diseases characterized by hyperproliferation of keratinocytes and/or T cells.